In 2018, a colleague and I, together with a team of Greenlandic research assistants, conducted one of the most comprehensive ...

Banreservas grew its factoring portfolio by 63.5% in 2024 over the previous year. The bank also launched “Factoring ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential.

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Taiwanese residents in Denmark staged a protest outside the Danish Parliament on Monday, opposing a new government policy ...

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for ...

President Trump’s executive order on offshore wind, “Temporary Withdrawal of All Areas on the Outer Continental Shelf from ...

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

While not singled out by name, authorities in Copenhagen raise concerns about mariner and environmental safety ...

The real question isn’t whether the U.S. should engage, but how — and whether we act before Beijing or Moscow fill the void.

U.S. stock futures point lower as investors evaluate disappointing tech earnings, shares of Alphabet drop as the Google parent's cloud revenue falls short of estimates, and Advanced Micro Devices ...